Identification
- Summary
Potassium chloride is a potassium salt used to treat hypokalemia.
- Brand Names
- Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol
- Generic Name
- Potassium chloride
- DrugBank Accession Number
- DB00761
- Background
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.1
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Potassium chloride (DB00761)
- Weight
- Average: 74.551
Monoisotopic: 73.932559568 - Chemical Formula
- ClK
- Synonyms
- Chlorid draselny
- Chloride of potash
- Kaliumchlorid
- KCl
- Monopotassium chloride
- Muriate of potash
- Potassium chloride
- Sylvite
- External IDs
- B1653
- E 508
- E-508
- INS NO.508
- INS-508
- NSC-77368
Pharmacology
- Indication
For use as an electrolyte replenisher and in the treatment of hypokalemia.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Dehydration Combination Product in combination with: Sodium chloride (DB09153), Sodium acetate (DB09395), Magnesium chloride (DB09407) •••••••••••• •••••••• Used in combination to treat Dry mouth Combination Product in combination with: Calcium chloride (DB01164), Magnesium chloride (DB09407) •••••••••••• •••••••• Treatment of Hypokalemia •••••••••••• ••••••• •••••••• ••••••• Prophylaxis of Hypokalemia •••••••••••• ••••••• •••••••• ••••••• Used in combination to treat Hypotonic dehydration Combination Product in combination with: Lactic acid (DB04398), Calcium chloride (DB01164), Magnesium chloride (DB09407), Sodium chloride (DB09153) •••••••••••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
- Mechanism of action
Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.
Target Actions Organism USolute carrier family 12 member 2 Not Available Humans USolute carrier family 12 member 1 binderHumans USolute carrier family 12 member 5 Not Available Humans USolute carrier family 12 member 6 Not Available Humans USolute carrier family 12 member 7 Not Available Humans USolute carrier family 12 member 4 Not Available Humans - Absorption
Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Potassium chloride may decrease the excretion rate of Abacavir which could result in a higher serum level. Acebutolol Potassium chloride may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium chloride may increase the hyperkalemic activities of Aceclofenac. Acemetacin Potassium chloride may increase the hyperkalemic activities of Acemetacin. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level. - Food Interactions
- Take with a full glass of water.
- Take with food. This reduces gastrointestinal irritation.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Chloride ion ionic Q32ZN48698 16887-00-6 VEXZGXHMUGYJMC-UHFFFAOYSA-M - Product Images
- International/Other Brands
- Kaon Cl / Kaon-CL 10 / Micro-K / Sando-K / Slow-K
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Chlorure de potassium Proamp Injection, solution, concentrate 0.15 g/1mL Intravenous Laboratoire Aguettant 2018-07-31 Not applicable US 
Epiklor Powder, for solution 1.5 g/1.77g Oral Epic Pharma, LLC 2010-02-01 2013-10-01 US Epiklor/25 Powder, for solution 1.875 g/2.21g Oral Epic Pharma, LLC 2010-02-01 2013-09-01 US HUMCO Potassium Chloride 10 Percent Liquid 100 mg/1mL Oral Humco Holding Group. Inc. 1979-01-01 2015-12-31 US K + 45 Liquid 251.6 g / L Baxter Laboratories 1990-12-31 Not applicable Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Klor Con M Tablet, extended release 1500 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 1998-11-20 Not applicable US 
Klor Con M Tablet, extended release 750 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 1998-11-20 Not applicable US Klor-Con Tablet, extended release 1500 mg/1 Oral Apace Packaging 2000-08-09 2014-09-30 US Klor-con Powder, for solution 1.5 g/1 Oral Upsher-Smith Laboratories, LLC 2017-10-23 Not applicable US Klor-Con M Tablet, extended release 1500 mg/1 Oral Aphena Pharma Solutions - Tennessee, Inc. 2011-01-18 2019-05-17 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ADDI-K Tablet, extended release 750 mg Oral บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด 2010-05-17 Not applicable Thailand 
APO-K TABLET 600 mg Tablet, film coated 600 mg Oral PHARMAFORTE SINGAPORE PTE LTD 1991-08-19 Not applicable Singapore 
APO-K TABLET 600MG (S/R) Tablet Oral PHARMAFORTE (MALAYSIA) SDN. BHD. 2020-09-08 Not applicable Malaysia 
Hi Potency Potassium Chloride Tablet, extended release 500 mg Oral Swiss Herbal Remedies Ltd. 1997-02-24 2001-08-02 Canada Kaochlor-20 Solution 3 g / 15 mL Oral Pfizer Canada Ulc 1995-12-31 2006-08-02 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image (20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USP Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (3.3 g / 100 mL) + Sodium chloride (300 mg / 100 mL) Solution Intravenous Baxter Laboratories 1978-12-31 Not applicable Canada (20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USP Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (900 mg / 100 mL) Solution Intravenous Baxter Laboratories 1990-12-31 Not applicable Canada (20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USP Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USP Potassium chloride (150 mg / 100 mL) + Sodium chloride (900 mg / 100 mL) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USP Potassium chloride (150 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Sodium chloride (200 mg / 100 mL) Solution Intravenous Baxter Laboratories 1989-12-31 2016-07-15 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETLI Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey 
BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 1000 ML SETSIZ Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETLI Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey BIOFLEKS 10 MEQ/L POTASYUM KLORUR %5 DEKSTROZ SOLUSYONU 500 ML SETSIZ Potassium chloride (10 mEq/L) + D-glucose monohydrate (5 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey BIOFLEKS 20MEQ/L KCL%5DEK 100 ML SOLUSYON SETSIZ Potassium chloride (20 mEq/L) + D-glucose monohydrate (5 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2013-01-29 Not applicable Turkey
Categories
- ATC Codes
- A12BA51 — Potassium chloride, combinationsB05XA01 — Potassium chloride
- B05XA — Electrolyte solutions
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Agents causing hyperkalemia
- Alimentary Tract and Metabolism
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Chlorides
- Chlorine Compounds
- Drugs that are Mainly Renally Excreted
- Electrolyte Solutions
- Hemodialysis Solution
- I.V. Solution Additives
- Mineral Supplements
- Minerals
- Potassium Compounds
- Potassium Salt
- Replacement Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal salts
- Sub Class
- Alkali metal chlorides
- Direct Parent
- Alkali metal chlorides
- Alternative Parents
- Inorganic chloride salts
- Substituents
- Alkali metal chloride / Inorganic chloride salt / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- potassium salt, inorganic chloride (CHEBI:32588)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 660YQ98I10
- CAS number
- 7447-40-7
- InChI Key
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M
- InChI
- InChI=1S/ClH.K/h1H;/q;+1/p-1
- IUPAC Name
- potassium chloride
- SMILES
- [Cl-].[K+]
References
- Synthesis Reference
Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.
US5057208- General References
- Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness. [Link]
- External Links
- Human Metabolome Database
- HMDB0303551
- KEGG Drug
- D02060
- PubChem Compound
- 4873
- PubChem Substance
- 46506038
- ChemSpider
- 4707
- 8591
- ChEBI
- 32588
- ChEMBL
- CHEMBL1200731
- Therapeutic Targets Database
- DAP000828
- PharmGKB
- PA451055
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Potassium_chloride
- FDA label
- Download (632 KB)
- MSDS
- Download (72.6 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Health Services Research Colorectal Cancer 1 4 Completed Not Available Colonoscopy 1 4 Completed Basic Science Blood Pressures / Hypertension 1 4 Completed Basic Science Functional Constipation (FC) / Irritable Bowel Syndrome Characterized by Constipation 1 4 Completed Diagnostic Colon Adenomas / Colon Lesions / Colon Polyps 1
Pharmacoeconomics
- Manufacturers
- Novo nordisk inc
- Savage laboratories inc div altana inc
- Kv pharmaceutical co
- Teva pharmaceuticals usa inc
- Watson laboratories inc florida
- Abraxis pharmaceutical products
- Akorn inc
- App pharmaceuticals llc
- B braun medical inc
- Baxter healthcare corp anesthesia and critical care
- Baxter healthcare corp
- Gd searle llc
- Hospira inc
- International medication system
- Eli lilly and co
- Luitpold pharmaceuticals inc
- Miles laboratories inc
- Pharma serve inc sub torigian laboratories
- Watson laboratories inc
- Future pak ltd
- Upsher smith laboratories inc
- Apothecon inc div bristol myers squibb
- Abbott laboratories pharmaceutical products div
- Copley pharmaceutical inc
- Eurand america inc
- Schering corp
- Novartis pharmaceuticals corp
- Upsher-Smith Laboratories Inc.
- Packagers
- Abbott Laboratories Ltd.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Alaven Pharmaceutical
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apace Packaging
- Apothecon
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- B. Braun Melsungen AG
- Baxter International Inc.
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Cardinal Health
- Caremark LLC
- Century Pharmaceuticals Inc.
- Chemrich Laboratories Inc.
- Comprehensive Consultant Services Inc.
- Corvit Pharmaceuticals
- Coupler Enterprises Inc.
- Dept Health Central Pharmacy
- DHHS Program Support Center Supply Service Center
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Edwards Pharmaceuticals
- Epic Pharma LLC
- Ethex Corp.
- Eurand Pharmaceuticals Inc.
- Forest Pharmaceuticals
- General Injectables and Vaccines Inc.
- H and H Laboratories
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hospira Inc.
- Humco
- John Ross Chemical Ltd.
- Kaiser Foundation Hospital
- KV Pharmaceutical Co.
- Laboratoires Upsa
- Lake Erie Medical and Surgical Supply
- Legacy Pharmaceuticals Packaging LLC
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mallinckrodt Inc.
- Mckesson Corp.
- Mead Johnson and Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neighborcare Repackaging Inc.
- Neuman Distributors Inc.
- Novartis AG
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Association
- Pharmaceutical Packaging Center
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmacia Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Qualitest
- Rebel Distributors Corp.
- Remedy Repack
- Sandhills Packaging Inc.
- Sandoz
- Savage Labs
- Schering Corp.
- Schering-Plough Inc.
- Southwood Pharmaceuticals
- Summit Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Ther-Rx Corp.
- Tower Laboratories Ltd.
- Tya Pharmaceuticals
- United Research Laboratories Inc.
- Upsher Smith Laboratories
- Va Cmop Dallas
- Vangard Labs Inc.
- Vintage Pharmaceuticals Inc.
- Warrick Pharmaceuticals Corp.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Dosage Forms
Form Route Strength Liquid Intravenous Injection Intravenous 50 g/L Solution Hemodialysis 0.257 g/1000ml Tablet, extended release Oral 750 mg Solution Irrigation; Parenteral Powder, for solution Intraocular Solution Intraocular Tablet, film coated Oral 600 mg Solution Ophthalmic Kit; powder, for solution; tablet, delayed release Oral Solution Hemodialysis; Intravenous Solution Hemodialysis; Intravenous 0.187 g/L Concentrate; kit; solution Ophthalmic Kit; solution Intraocular Solution Intra-arterial Injection, solution, concentrate Intravenous 0.15 g/1mL Solution Intravenous 1.49 g Solution Parenteral 0.149 g Solution Intravenous 20 mEq/mL Solution Intravenous 10 g Solution Intravenous 1.491 g Solution Intravenous 149000 g Powder, for solution Nasogastric Solution Intravenous 0.27 g/1000ml Tablet Oral 750.000 mg Solution Irrigation Drug delivery system Oral 105.00 g Injection Other Injection Other 16 mmol/20ml Injection Intravenous Cream; kit; liquid; ointment; tablet; tablet, chewable; tablet, film coated Oral; Topical Solution Intravenous 4.21 g/1000ml Solution Parenteral 300.000 mg Tablet, effervescent Oral Granule, for solution Oral Solution Oral 0.2600 g Solution Intrathecal Injection Intrathecal Solution Intravenous; Subcutaneous Powder Oral Powder, for solution Oral 1.5 g/1.77g Powder, for solution Oral 1.875 g/2.21g Granule, for solution Oral 64 g Solution, concentrate Hemodialysis Solution Intravenous 0.745 g Spray Oral Aerosol, spray Oral Solution Other 57 g/100ml Solution Unknown Solution Extracorporeal Powder, for solution Nasogastric; Oral Solution Solution Hemodialysis Solution Hemodialysis 7.77 g/l Solution Hemodialysis 8.46 g/l Solution Intravenous 600.0 mg Solution Hemodialysis 8.8 g/l Solution Hemodialysis 8.85 g/l Liquid Hemodialysis Solution Hemodialysis 6.77 g/l Tablet, extended release Oral 500 mg Solution Oral Liquid Oral 100 mg/1mL Drug delivery system Oral 20.000 g Patch Topical Solution, concentrate Intravenous 100 mmol/L Solution, concentrate Intravenous 200 mmol/L Solution, concentrate Intravenous 400 mmol/L Injection Parenteral 746 mg Injection Parenteral 1.49 g Injection Parenteral 2.24 g Injection Parenteral 2.98 g Injection Parenteral Liquid Intraocular Solution Intravenous Liquid 251.6 g / L Liquid Oral 750 mg / 15 mL Powder, for solution Oral 1.5 g / 3 g Tablet, extended release Oral 1.5 g Elixir Oral 10 g Powder, for solution Oral 1.86 g / 7.8 g Tablet Oral 900 mg Liquid Oral 20 meq/15mL Liquid Oral 40 meq/15mL Tablet, film coated, extended release Oral 1500 mg/1 Tablet, film coated, extended release Oral 750 mg/1 Solution Intravenous 74.5 mg Emulsion Parenteral 20.000 g Injection, emulsion Intravenous Injection Intravenous 1.6 g/l Capsule, extended release Oral 600 mg Tablet Oral 500.000 mg Tablet, extended release Oral 750 mg / tab Solution Intravenous 1.491 g/20ml Injection, solution, concentrate Intravenous 74.5 mg/ml Injection, solution, concentrate Intravenous 15 % Solution Parenteral 1.49 g Solution Oral 10 % Solution Oral 3 g / 15 mL Powder, for solution Oral 1.5 g / pck Tablet, sugar coated Oral 600 mg Solution Oral 200 mg / mL Powder, for solution Oral 1.875 g/1 Powder, for solution Oral 20 meq/1 Tablet, extended release Oral 750 mg/1 Tablet, extended release Oral 10 meq/1 Tablet, extended release Oral 1125 mg/1 Tablet, extended release Oral 20 meq/1 Tablet, film coated, extended release Oral Injection Intravenous 20 mg/100ml Solution, for slush Irrigation Injection Intravenous 0.027 % w/v Solution Intravenous 7.5 % Capsule Oral Drug delivery system Oral Emulsion Topical Capsule, delayed release Oral 600 mg Capsule, extended release Oral 600 mg / cap Capsule, extended release Oral 750 mg/1 Capsule, extended release Oral 600 mg/1 Capsule, extended release Oral 750 mg / src Liquid Buccal Spray Buccal Powder, for solution Oral 13.125 g Powder, for solution Oral 13.125 G Injection, solution, concentrate Oral Kit Oral Kit; solution Oral Solution Intravenous 4.410 g Injection, solution Hemodialysis; Intravenous Kit; solution Intraocular; Irrigation Granule, effervescent Oral Tablet, extended release Oral 600 mg Injection, emulsion; injection, solution Intravenous Injection, solution, concentrate Intravenous Emulsion Intravenous Emulsion Intravenous 4 g Solution, concentrate Oral Solution Intraocular; Ophthalmic Solution Extracorporeal; Intrabiliary; Intracardiac Injection Intravenous Solution Oral 1.188 g Powder Oral 238.33 g Liquid Oral Emulsion Intravenous 3 g Irrigant Irrigation Injection, solution Intravenous Injection Intravenous 30 mg/100ml Injection, solution Intra-arterial Kit; powder, for solution Oral Powder, for solution Oral 0.75 g/0.79g Powder, for solution Oral Injection, solution Intravenous Injection, solution Parenteral Solution Oral Solution Parenteral Injection, solution, concentrate Intravenous Injection, solution, concentrate Intravenous 2 MEQ/ML Injection, solution, concentrate Intravenous 3 MEQ/ML Capsule Oral 750 mg/1 Capsule, coated, extended release Oral 10 meq/1 Capsule, coated, extended release Oral 8 meq/1 Capsule, extended release Oral 10 meq/1 Capsule, extended release Oral 8 meq/1 For solution Oral 1.5 g/1.58g For solution Oral 1.5 g/1.54g For solution Oral 1.5 g/1.56g Injection Injection Intravenous 10 meq/50mL Injection Intravenous 10 meq/100mL Injection Intravenous 14.9 mg/1mL Injection Intravenous 150 g/1000mL Injection Intravenous 20 meq/50mL Injection Intravenous 20 meq/100mL Injection Intravenous 29.8 mg/1mL Injection Intravenous 40 meq/100mL Injection Intravenous 7.45 mg/1mL Injection, solution Intravenous 10 meq/100mL Injection, solution Intravenous 14.9 g/1000mL Injection, solution Intravenous 200 meq/1000mL Injection, solution Intravenous 22.4 g/1000mL Injection, solution Intravenous 29.8 g/1000mL Injection, solution Intravenous 30 meq/100mL Injection, solution Intravenous 400 meq/1000mL Injection, solution Intravenous 7.46 g/1000mL Injection, solution, concentrate Intravenous 149 mg/1mL Injection, solution, concentrate Intravenous 2 meq/1mL Injection, solution, concentrate Parenteral 14.9 g/100mL Liquid Oral 40 meq/30mL Powder Not applicable 50 kg/50kg Powder Oral 20 meq/1.5g Powder, for solution Oral 1.5 g/1.74g Powder, for solution Oral 1.5 g/1 Powder, for solution Oral 25 meq/1 Solution Oral 1.3 meq/1mL Solution Oral 1.5 g/15mL Solution Oral 2.6 meq/1mL Solution Oral 20 meq/30mL Solution Oral 20 meq/15mL Solution Oral 3 g/30mL Solution Oral 3 g/15mL Solution Oral 40 meq/15mL Tablet Oral 10 meq/1 Tablet Oral 1125 mg/1 Tablet Oral 1500 mg/1 Tablet Oral 750 mg/1 Tablet, extended release Oral 1500 mg/1 Tablet, extended release Oral 8 meq/1 Tablet, film coated, extended release Oral 10 meq/1 Tablet, film coated, extended release Oral 600 mg/1 Tablet, film coated, extended release Oral 8 meq/1 Solution Intravenous 50.0 g/1000ml Solution Intravenous 3.00 g/1000ml Powder Hemodialysis 12.5 g / vial Powder Hemodialysis 13 g / vial Powder Hemodialysis 15.26 g / vial Powder Hemodialysis 25 g / vial Powder Hemodialysis 7.65 g / vial Tablet Oral 20 meq/1 Capsule Oral 600 mg/1 Powder, for solution Hemodialysis 7.55 g / vial Solution Intravenous 20 mEq / 10 mL Solution Intravenous 200 mEq / 100 mL Solution Intravenous 149 mg / mL Solution Intravenous 2 mEq / mL Powder, for solution Oral 1.5 g/1.58g Liquid Intravenous 2 mEq / mL Solution Intravenous 1.784 mg / mL Solution Intravenous 2.384 mg / mL Liquid Intravenous 149 mg / mL Liquid Intravenous 22.4 mg / mL Solution Intravenous 10 mEq / 100 mL Solution Intravenous 20 mEq / 100 mL Solution Intravenous 250 mg/1ml Solution Intravenous 40 mEq / 100 mL Injection Intravenous 746 mg/100ml Injection Intravenous 746 mg/50ml Injection Intravenous 1.49 g/50ml Solution Oral 500 mg/5ml Tablet Oral 600 mg Tablet, extended release Oral 600 mg / tab Powder Hemodialysis 6.2 g / pck Injection, solution Intravenous 225 mg/1ml Injection, solution Intravenous 75 mg/1ml Injection, solution Intravenous 22.5 % Injection, solution Intravenous 7.5 % Solution Oral 40 meq/30mL Tablet Oral Kit Hemodialysis Injection Intravenous 0.21 g/100ml Douche Vaginal Solution Intravenous 0.1 g/500ml Solution Irrigation; Topical Injection, solution Irrigation Liquid Oral 10 % Solution Buccal; Oral; Topical Aerosol Oral Granule Solution Intravenous 50.000 mL Tablet, extended release Oral 600 mg/1 Emulsion Intravenous 13.000 g Solution Oral 11.700 mg Injection, solution Parenteral Powder, for solution Oral 2.9 g Solution Intraocular; Irrigation Solution Conjunctival; Ophthalmic Solution Oral 0.012 g Concentrate Intravenous drip Injection Intravenous 7.45 g/100ml Solution Parenteral Liquid Intravenous 150 mg / mL Emulsion Parenteral Capsule Oral Solution Intravenous 0.3675 g/1000ml Tablet Oral Liquid Irrigation Solution Intravenous; Irrigation Solution Intravenous 10 mg/2ml Powder Oral 20.00 g Tablet Oral 500 mg Liquid Ophthalmic Syrup 500 mg/5ml Solution Intravenous 150 mg/1ml Tablet, delayed release Oral 500 mg Elixir Oral 500 mg/5ml - Prices
Unit description Cost Unit Klor-Con 100 20meq Packets Box 106.77USD box Kay Ciel 30 20meq Packets Box 58.99USD box Rum-K-SF 15% Liquid 473ml Bottle 45.98USD bottle Klor-Con 30 25meq Packets Box 36.99USD box Colyte 240 gm Solution 26.0USD bottle Colyte-Flavored 240 gm Solution 18.17USD bottle K-Lor 20meq Packets 1.92USD packet K-lyte tablet eff 1.43USD tablet K-lyte-cl 25 meq tablet eff 1.43USD tablet Micro-K 10meq capsule 1.41USD capsule Micro-K 8meq capsule 1.21USD capsule Potassium cl 25 meq tablet eff 0.94USD tablet Micro-k 10 meq extencaps 0.91USD each Potassium Chloride CR 10meq capsule 0.9USD capsule Potassium Chloride CR 8meq capsule 0.87USD capsule K-Tabs 10meq Controlled Release Tabs 0.68USD tab K-tab er 10 meq tablet 0.66USD tablet Kaochlor-eff 20 meq tablet 0.59USD tablet K-tab 10 meq tablet sa 0.58USD tablet K-Lyte 25 meq Effervescent Tablet 0.58USD tablet Klor-con m20 tablet 0.57USD tablet Klor-Con/EF 25meq Effervescent Tabs 0.57USD tab Klor-Con 8meq Controlled Release Tabs 0.56USD tab Klor-Con M20 20meq Controlled Release Tabs 0.55USD tab Potassium Chloride Crys CR 20meq Controlled Release Tabs 0.53USD tab Potassium cl 20 meq tablet er 0.52USD tablet Potassium cl 20 meq tablet sa 0.52USD tablet Klor-con 10 meq tablet 0.5USD tablet Klor-con m15 tablet 0.5USD tablet Klotrix 10meq Controlled Release Tabs 0.5USD tab Potassium cl er 20 meq tablet 0.49USD tablet Klor-con-ef 25 meq tablet eff 0.4USD tablet Micro-k 8 meq extencaps 0.34USD each Kaon-Cl-10 10meq Controlled Release Tabs 0.3USD tab Klor-con m10 tablet 0.3USD tablet Potassium cl er 10 meq tablet 0.3USD tablet Potassium cl 10 meq tablet sa 0.29USD tablet Potassium Chloride Crys CR 10meq Controlled Release Tabs 0.28USD tab Potassium Chloride CR 10meq Controlled Release Tabs 0.27USD tab Potassium cl er 8 meq tablet 0.26USD tablet Kaon-cl 10 meq tablet sa 0.23USD tablet Potassium cl 2 meq/ml vial 0.23USD ml K-Dur 20 meq Sustained-Release Tablet 0.21USD tablet Potassium Chloride CR 8meq Controlled Release Tabs 0.18USD tab Klor-con 8 meq tablet 0.16USD tablet Slow K 8 meq Sustained-Release Tablet 0.16USD tablet Micro-K Extencaps 8 meq Sustained-Release Capsule 0.1USD capsule Apo-K 8 meq Sustained-Release Tablet 0.09USD tablet Potassium Chloride 40 Meq/15ml(20%) Liquid 0.06USD ml Potassium Chloride 20 Meq/15ml(10%) Liquid 0.03USD ml Potassium chloride crystals 0.02USD g K-10 Oral Liquid 1.33 meq/ml Liquid 0.02USD ml Colyte with flavor packets 0.01USD ml Pms - Potassium Chloride 1.33 meq/ml Liquid 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7291324 No 2007-11-06 2022-10-22 US US7169381 No 2007-01-30 2024-09-01 US US7658914 No 2010-02-09 2024-09-01 US US7084130 No 2006-08-01 2021-11-29 US US9326969 No 2016-05-03 2033-09-10 US US9592252 No 2017-03-14 2032-08-11 US US9707297 No 2017-07-18 2033-09-10 US US8999313 No 2015-04-07 2033-09-10 US US10016504 No 2018-07-10 2033-09-10 US US10646512 No 2020-05-12 2032-03-25 US US10792306 No 2020-10-06 2032-03-09 US US10780112 No 2020-09-22 2032-03-09 US US10143656 No 2018-12-04 2037-08-04 US US10918723 No 2021-02-16 2033-09-10 US US11033498 No 2021-06-15 2037-08-04 US US11382864 No 2017-08-04 2037-08-04 US US11529368 No 2012-03-09 2032-03-09 US US11638697 No 2017-08-04 2037-08-04 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 770 °C Not Available water solubility Freely soluble Not Available - Predicted Properties
Property Value Source Water Solubility 91.5 mg/mL ALOGPS logP -0.05 ALOGPS logP 0.2 Chemaxon logS 0.09 ALOGPS pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9445 Blood Brain Barrier + 0.975 Caco-2 permeable + 0.6764 P-glycoprotein substrate Non-substrate 0.9039 P-glycoprotein inhibitor I Non-inhibitor 0.9891 P-glycoprotein inhibitor II Non-inhibitor 0.9866 Renal organic cation transporter Non-inhibitor 0.9219 CYP450 2C9 substrate Non-substrate 0.8116 CYP450 2D6 substrate Non-substrate 0.717 CYP450 3A4 substrate Non-substrate 0.7571 CYP450 1A2 substrate Non-inhibitor 0.7551 CYP450 2C9 inhibitor Non-inhibitor 0.8594 CYP450 2D6 inhibitor Non-inhibitor 0.9314 CYP450 2C19 inhibitor Non-inhibitor 0.8365 CYP450 3A4 inhibitor Non-inhibitor 0.9576 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9002 Ames test Non AMES toxic 0.6808 Carcinogenicity Carcinogens 0.7523 Biodegradation Ready biodegradable 0.6815 Rat acute toxicity 1.9786 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9433 hERG inhibition (predictor II) Non-inhibitor 0.9634
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 109.06206 predictedDeepCCS 1.0 (2019) [M+H]+ 110.78577 predictedDeepCCS 1.0 (2019) [M+Na]+ 117.68356 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A2
- Uniprot ID
- P55011
- Uniprot Name
- Solute carrier family 12 member 2
- Molecular Weight
- 131445.825 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A1
- Uniprot ID
- Q13621
- Uniprot Name
- Solute carrier family 12 member 1
- Molecular Weight
- 121449.13 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [Article]
- Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [Article]
- Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
- Gene Name
- SLC12A5
- Uniprot ID
- Q9H2X9
- Uniprot Name
- Solute carrier family 12 member 5
- Molecular Weight
- 126182.49 Da
References
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [Article]
- Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [Article]
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Rubidium ion transmembrane transporter activity
- Specific Function
- Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
- Gene Name
- SLC12A6
- Uniprot ID
- Q9UHW9
- Uniprot Name
- Solute carrier family 12 member 6
- Molecular Weight
- 127615.745 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
- Gene Name
- SLC12A7
- Uniprot ID
- Q9Y666
- Uniprot Name
- Solute carrier family 12 member 7
- Molecular Weight
- 119104.84 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
- Gene Name
- SLC12A4
- Uniprot ID
- Q9UP95
- Uniprot Name
- Solute carrier family 12 member 4
- Molecular Weight
- 120648.73 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A2
- Uniprot ID
- P55011
- Uniprot Name
- Solute carrier family 12 member 2
- Molecular Weight
- 131445.825 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A1
- Uniprot ID
- Q13621
- Uniprot Name
- Solute carrier family 12 member 1
- Molecular Weight
- 121449.13 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [Article]
- Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [Article]
- Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
- Gene Name
- SLC12A5
- Uniprot ID
- Q9H2X9
- Uniprot Name
- Solute carrier family 12 member 5
- Molecular Weight
- 126182.49 Da
References
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [Article]
- Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [Article]
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Rubidium ion transmembrane transporter activity
- Specific Function
- Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
- Gene Name
- SLC12A6
- Uniprot ID
- Q9UHW9
- Uniprot Name
- Solute carrier family 12 member 6
- Molecular Weight
- 127615.745 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
- Gene Name
- SLC12A7
- Uniprot ID
- Q9Y666
- Uniprot Name
- Solute carrier family 12 member 7
- Molecular Weight
- 119104.84 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
- Gene Name
- SLC12A4
- Uniprot ID
- Q9UP95
- Uniprot Name
- Solute carrier family 12 member 4
- Molecular Weight
- 120648.73 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [Article]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [Article]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55